Production (Stage)
Camp4 Therapeutics Corporation
CAMP
$2.00
-$0.005-0.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 350.00K | 350.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 350.00K | 350.00K |
| Cost of Revenue | -- | -- | -- | 39.78M | 40.29M |
| Gross Profit | -- | -- | -- | -39.43M | -39.94M |
| SG&A Expenses | -- | -- | -- | 12.02M | 11.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 51.81M | 52.07M |
| Operating Income | -- | -- | -- | -51.46M | -51.72M |
| Income Before Tax | -- | -- | -- | -49.65M | -49.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -49.65 | -49.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -49.65M | -49.44M |
| EBIT | -- | -- | -- | -51.46M | -51.72M |
| EBITDA | -- | -- | -- | -49.73M | -50.01M |
| EPS Basic | -- | -- | -- | -112.34 | -118.86 |
| Normalized Basic EPS | -- | -- | -- | -70.21 | -74.29 |
| EPS Diluted | -- | -- | -- | -112.34 | -118.86 |
| Normalized Diluted EPS | -- | -- | -- | -70.21 | -74.29 |
| Average Basic Shares Outstanding | -- | -- | -- | 1.77M | 1.67M |
| Average Diluted Shares Outstanding | -- | -- | -- | 1.77M | 1.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |